Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

2009 • 1,268 citations

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

2013 • 1,068 citations

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

2013 • 1,027 citations

FOXA1 is a key determinant of estrogen receptor function and endocrine response

2010 • 798 citations

27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology

2013 • 715 citations

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

2010 • 614 citations

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

2013 • 570 citations

Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

2014 • 565 citations

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

2008 • 480 citations

Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial

2013 • 301 citations

Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells.

1995 • 298 citations

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

2009 • 297 citations

Pathways to tamoxifen resistance

2007 • 272 citations

Treatment of Estrogen Receptor-Positive Breast Cancer

2013 • 260 citations

Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled Study

2007 • 233 citations

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

2001 • 214 citations

PIK3CAandPIK3CBInhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer

2009 • 200 citations

Systematic identification of signaling pathways with potential to confer anticancer drug resistance

2014 • 181 citations

Estrogen Receptor Expression and Function in Long-Term Estrogen-Deprived Human Breast Cancer Cells¹

1998 • 173 citations

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

2003 • 137 citations

Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease

2013 • 134 citations

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)

2006 • 134 citations

Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.

2001 • 130 citations

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

2012 • 129 citations

The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy

2011 • 124 citations

Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells

1995 • 123 citations

The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor α and Cyclin D1

2011 • 118 citations

Full Activation of Estrogen Receptor α Activation Function-1 Induces Proliferation of Breast Cancer Cells

2003 • 88 citations

Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells

2007 • 88 citations

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis

2010 • 87 citations

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment

2011 • 75 citations

Estrogen-related receptor-α antagonist inhibits both estrogen receptor–positive and estrogen receptor–negative breast tumor growth in mouse xenografts

2009 • 74 citations

Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients

2014 • 61 citations

From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs)

2014 • 42 citations

New Global Survey Shows an Increasing Cancer Burden

2014 • 40 citations

THE CHIMPANZEE (PAN TROGLODYTES) AS A PHARMACOKINETIC MODEL FOR SELECTION OF DRUG CANDIDATES: MODEL CHARACTERIZATION AND APPLICATION

2004 • 27 citations

Exemestane for Breast Cancer Prevention: A Critical Shift?

2012 • 23 citations

An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition

2011 • 23 citations

Nursing Care Left Undone in European Hospitals

2014 • 21 citations

Multiple‐Dose, Safety, Pharmacokinetics, and Pharmacodynamics of a New Selective Estrogen Receptor Modulator, ERA‐923, in Healthy Postmenopausal Women

2002 • 18 citations

Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer

2013 • 11 citations

Cited By (0)

No citing papers found in database